CVS Gets Higher Target as Bernstein Cites Management Confidence

Group 1 - CVS Health Corporation is recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - Bernstein raised the price target for CVS to $87 from $86, maintaining a Market Perform rating, citing increased confidence in management and market leadership [2] - CVS raised its 2025 profit forecast, indicating progress in its turnaround plan and a focus on enhancing consumer experiences [3] Group 2 - The company launched a new consumer app aimed at integrating services and creating new revenue opportunities, following significant changes including cost-cutting and market exits [4] - CVS forecasts total revenue of at least $400 billion for 2026, which is below the analyst expectation of $419.26 billion, with growth anticipated from Aetna and CVS Caremark [5] - CVS operates as a diversified healthcare company with services in pharmacy, retail health, and long-term care [5]